Vulvovaginal Graft-Versus-Host Disease

作者：Kornik Rachel I; Rustagi Alison S

来源：Obstetrics and Gynecology Clinics of North America, 2017, 44(3): 475-+.

DOI：10.1016/j.ogc.2017.05.007

• Graft-versus-host disease
• Vulvovaginal
• Genital
• Hematopoietic stem cell transplant

Vulvovaginal chronic graft-versus-host disease (cGVHD) is an underrecognized complication of stem cell transplantation. Early recognition may prevent severe sequelae. Genital involvement is associated with oral, ocular, and skin manifestations. Treatment includes topical immunosuppression, dilator use, and adjuvant topical estrogen. Clinical and histologic features may mimic other inflammatory vulvar conditions. In the right clinical context, these findings are diagnostic of cGVHD. Female recipients of allo-hematopoietic stem cell transplantation (HCT) are at higher risk of condylomas, cervical dysplasia, and neoplasia. The National Institutes of Health publishes guidelines for the diagnosis, grading, management, and supportive care for HCT patients by organ system.